Derwent London — TickStock

Derwent London plc is the largest London office-focused real estate investment trust, owning and managing a portfolio of 5.3 million square feet of commercial property valued at £5.1 billion as of December 2025, predominantly in central London's West End and areas bordering the City. The company creates value through property regeneration and mixed-use development, exemplified by projects such as 25 Baker Street, which integrates retail, residential and office space. As a long-term investor in London's prime office markets, Derwent London operates with a focus on sustainable, high-specification asset repositioning.

Sector: Pharma
Market: MAINMARKET

Identifiers

Ticker: DLN
Market: MAINMARKET
ISIN: GB0002652740
LEI: 213800BXKQ9KZNUR1M61

Learn more on:

Wikidata GLEIF Companies House

Timeline

Derwent London collects £160m from two central London disposals

More in Pharma

Physiomics promotes Head of Biometrics to Chief Operating Officer

Health & Bio Today: Oxford BioDynamics appoints new CEO and lands US partnership, Futura Medical, Poolbeg Pharma, Rua Life Sciences

SSE's transmission unit eyes £12bn grid update investment pipeline

Poolbeg Pharma wins South Africa patent for POLB 001 to 2038

Futura Medical WSD4000 studies show superiority ahead of pivotal trial

Health & Bio Today: Creo Medical lifts FY26 guidance after Q1 beat, Verici Dx, Futura Medical, genedrive, AstraZeneca

AstraZeneca's Datroway wins EU approval recommendation for first-line triple-negative breast cancer

Health & Bio Today: Physiomics flags record pipeline after boardroom overhaul, Crism Therapeutics, Panther Securities, Beximco Pharmaceuticals

Crism Therapeutics shares rose after FDA Orphan Drug Designation

Physiomics flags record commercial pipeline after boardroom overhaul

Beximco Pharma posts 11% revenue rise as export sales surge 38%

Browse by Sector

Market reports

Energy & Resources

Financials

Technology

Healthcare

Industrials

Consumer